Radioembolization with yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: Efficacy, safety and prognostic factors

Oncology (Switzerland)

Volumn 86, Issue 1, 2014, Pages 24-32

  Michl, M ^a   Haug, A R ^b   Jakobs, T F ^d   Paprottka, P ^c   Hoffmann, R T ^e   Bartenstein, P ^b   Boeck, S ^a   Haas, M ^a   Laubender, R P ^c   Heinemann, V ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b European CyberKnife Center Munich Barmherzige Brüder Hospital Munich   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Liver metastases; Pancreatic cancer; Radioembolization; Yttrium 90

Indexed keywords

C REACTIVE PROTEIN; CA 19-9 ANTIGEN; GEMCITABINE; YTTRIUM 90; CISPLATIN; FLUORODEOXYGLUCOSE F 18; RADIOACTIVE MICROSPHERE; UNCLASSIFIED DRUG; YTTRIUM 90 MICROSPHERE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CHEMOEMBOLIZATION; CHOLANGITIS; CHOLESTASIS; CLINICAL ARTICLE; COHORT ANALYSIS; DUODENUM ULCER; FATIGUE; FEMALE; FEVER; HUMAN; LIVER ABSCESS; LIVER METASTASIS; MALE; MIDDLE AGED; NAUSEA; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SAFETY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SELECTIVE INTERNAL RADIATION THERAPY; SPLEEN INFARCTION; STOMACH ULCER; VOMITING; ADJUVANT THERAPY; ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG SAFETY; INCIDENTAL FINDING; OUTCOME ASSESSMENT; RADIATION INDUCED LIVER DISEASE; RADIATION INJURY; SALVAGE THERAPY; SIDE EFFECT; SURVIVAL RATE; TUMOR VOLUME;

ADULT; AGED; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; YTTRIUM RADIOISOTOPES;

EID: 84891683695     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000355821     Document Type: Article

References (37)

1. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413
2. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966
3. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825
4. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Ignacio Bilbao J, et al: Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology 2011; 54: 868-878
5. Jakobs TF, Hoffmann RT, Dehm K, Trumm C, Stemmler HJ, Tatsch K, La Fougere C, Murthy R, Helmberger TK, Reiser MF: Hepatic yttrium-90 radioembolization of chemotherapyrefractory colorectal cancer liver metastases. J Vasc Interv Radiol 2008; 19: 1187-1195
6. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL: Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: A critical appraisal of 48 cases. Ann Surg 2010; 251: 910-916
7. Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, Murthy R, Rose S, Warner RR, Liu D, et al: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90 Y-microspheres: Early results in 148 patients. Am J Clin Oncol 2008; 31: 271-279
8. King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, Morris DL: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113: 921-929
9. Saxena A, Bester L, Chua TC, Chu FC, Morris DL: Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: A preliminary assessment of this novel treatment option. Ann Surg Oncol 2010; 17: 484-491
10. Haug AR, Heinemann V, Bruns CJ, Hoffmann R, Jakobs T, Bartenstein P, Hacker M: 18 F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90 Y microspheres. Eur J Nucl Med Mol Imaging 2011; 38: 1037-1045
11. Jakobs TF, Hoffmann RT, Fischer T, Stemmler HJ, Tatsch K, La Fougere C, Murthy R, Reiser MF, Helmberger TK: Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 2008; 19: 683-690
12. Bangash AK, Atassi B, Kaklamani V, Rhee TK, Yu M, Lewandowski RJ, Sato KT, Ryu RK, Gates VL, Newman S, et al: 90 Y radioembolization of metastatic breast cancer to the liver: Toxicity, imaging response, survival. J Vasc Interv Radiol 2007; 18: 621-628
13. Cianni R, Urigo C, Notarianni E, Saltarelli A, D'Agostini A, Iozzino M, Dornbusch T, Cortesi E: Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases. Radiol Med 2010; 115: 619-633
14. Jakobs TF, Hoffmann RT, Poepperl G, Schmitz A, Lutz J, Koch W, Tatsch K, Lubiensky A, Reiser MF, Helmberger T: Mid-Term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)yttrium resin-microspheres. Eur Radiol 2007; 17: 1320-1330
15. Cao C, Yan TD, Morris DL, Bester L: Radioembolization with yttrium-90 microspheres for pancreatic cancer liver metastases: Results from a pilot study. Tumori 2010; 96: 955-958
16. Coldwell D, Sangro B, Wasan H, Salem R, Kennedy A: General selection criteria of patients for radioembolization of liver tumors: An international working group report. Am J Clin Oncol 2011; 34: 337-341
17. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A 3rd, Espat J, Bilbao JI, Sharma RA, et al: Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68: 13-23
18. Mahnken AH, Spreafico C, Maleux G, Helmberger T, Jakobs TF: Standards of practice in transarterial radioembolization. Cardiovasc Intervent Radiol 2013; 36: 613-622
19. Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, Garafalo M, Liu D, Coldwell D, Savin M, et al: Treatment parameters and outcome in 680 treatments of internal radiation with resin 90 Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009; 74: 1494-1500
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247
21. Haug AR, Tiega Donfack BP, Trumm C, Zech CJ, Michl M, Laubender RP, Uebleis C, Bartenstein P, Heinemann V, Hacker M: 18 FFDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med 2012; 53: 371-377
22. Boeck S, Bruns CJ, Sargent M, Schafer C, Seufferlein T, Jauch KW, Heinemann V: Current oncological treatment of patients with pancreatic cancer in Germany: Results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society. Oncology 2009; 77: 40-48
23. Nair J, Liu C, Caridi J, Zlotecki R, George TJ Jr: Gastroduodenal ulcerations as a delayed complication of hepatic metastasis radioembolization. J Clin Oncol 2010; 28:e735-e736
24. Konda A, Savin MA, Cappell MS, Duffy MC: Radiation microsphere-induced GI ulcers after selective internal radiation therapy for hepatic tumors: An underrecognized clinical entity. Gastrointest Endosc 2009; 70: 561-567
25. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, et al: Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: A comprehensive report of longterm outcomes. Gastroenterology 2010; 138: 52-64
26. Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman DE Jr, Loehr SP, Overton C, Meranze S, Niedzwiecki J, Sailer S: Resin 90 Ymicrosphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience. Int J Radiat Oncol Biol Phys 2006; 65: 412-425
27. Stubbs RS: Portal hypertension and liver surgery following selective internal radiation therapy with 90 yttrium microspheres. J Clin Oncol 2006; 24:e15
28. Hoffmann RT, Paprottka PM, Schon A, Bamberg F, Haug A, Durr EM, Rauch B, Trumm CT, Jakobs TF, Helmberger TK, et al: Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: Factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012; 35: 105-116
29. Gong Z, Holly EA, Bracci PM: Survival in population-based pancreatic cancer patients: San Francisco Bay area, 1995-1999. Am J Epidemiol 2011; 174: 1373-1381
30. Mulcahy MF, Lewandowski RJ, Ibrahim SM, Sato KT, Ryu RK, Atassi B, Newman S, Talamonti M, Omary RA, Benson A 3rd, Salem R: Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 2009; 115: 1849-1858
31. Haas M, Laubender RP, Stieber P, Holdenrieder S, Bruns CJ, Wilkowski R, Mansmann U, Heinemann V, Boeck S: Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol 2010; 31: 351-357
32. Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Ibrahim S, Mulcahy MF, Kulik L, et al: Incidence of radiation pneumonitis after hepatic intra-Arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 2008; 31: 431-438
33. Crowder CD, Grabowski C, Inampudi S, Sielaff T, Sherman CA, Batts KP: Selective internal radiation therapy-induced extrahepatic injury: An emerging cause of iatrogenic organ damage. Am J Surg Pathol 2009; 33: 963-975
34. Mascarenhas NB, Mulcahy MF, Lewandowski RJ, Salem R, Ryu RK: Hepatic abscess after yttrium-90 radioembolization for islet-cell tumor hepatic metastasis. Cardiovasc Intervent Radiol 2010; 33: 650-653
35. Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, Murthy R, Ryu RK, Sato KT, Miller FH, et al: Biliary sequelae following radioembolization with yttrium-90 microspheres. J Vasc Interv Radiol 2008; 19: 691-697
36. Guha C, Kavanagh BD: Hepatic radiation toxicity: Avoidance and amelioration. Semin Radiat Oncol 2011; 21: 256-263
37. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF: Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995; 31: 1237-1248